GARDP Foundation

Mission & Goals

The Global Antibiotic R&D Partnership (GARDP) is a not-for-profit organization that works in partnership to develop new antibiotic treatments and expand access to them, specifically among the world’s most vulnerable populations. GARDP was created by WHO and DNDi in 2016 to ensure that everyone who needs antibiotics receives effective and affordable treatment, no matter where they live. We develop new treatments to manage drug-resistant bacterial infections, focusing on sexually transmitted infections, sepsis in newborns and infections in hospitalized adults and children. Our antibiotic development and access portfolio currently includes two approved treatments (cefiderocol and zoliflodacin - a novel oral treatment for treatment for gonorrhoea approved by the US FDA on 12 December 2025), and five investigational treatments (fosfomycin-amikacin, flomoxef-amikacin, fosfomycin-flomoxef, apramycin and BWC0977) for serious bacterial infections and sepsis in adults, children and newborns.